 In all arms, patients receive adjuvant temozolomide on days 1-5 as per standard treatment beginning 2 weeks post-glycosylated recombinant human interleukin-7 treatment. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. 